Long-acting	JJ
human	JJ
serum	NN
albumin-thioredoxin	NN
fusion	NN
protein	NN
suppresses	VBZ
bleomycin-induced	JJ
pulmonary	JJ
fibrosis	NN
progression	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
thought	VBN
to	TO
involve	VB
inflammatory	JJ
cells	NNS
and	CC
reactive	JJ
oxygen	NN
species	NNS
(	(
ROS	NN
)	)
,	,
such	JJ
as	IN
superoxide	NN
anion	NN
radical	NN
(	(
O2	CD
(	(
-	:
)	)
)	)
.	.

There	EX
is	VBZ
currently	RB
no	DT
effective	JJ
treatment	NN
of	IN
IPF	NN
.	.

We	PRP
previously	RB
developed	VBD
a	DT
human	JJ
serum	NN
albumin	NN
(	(
HSA	NN
)	)
-	:
thioredoxin	NN
1	CD
(	(
Trx	NN
)	)
fusion	NN
protein	NN
(	(
HSA-Trx	NN
)	)
designed	VBN
to	TO
overcome	VB
the	DT
unfavorable	JJ
pharmacokinetic	JJ
and	CC
short	JJ
pharmacological	JJ
properties	NNS
of	IN
Trx	NN
,	,
an	DT
antioxidative	JJ
and	CC
anti-inflammatory	JJ
protein	NN
.	.

In	IN
this	DT
study	NN
,	,
we	PRP
examined	VBD
the	DT
therapeutic	JJ
effect	NN
of	IN
HSA-Trx	NN
on	IN
an	DT
IPF	NN
animal	NN
model	NN
of	IN
bleomycin	NN
(	(
BLM	NN
)	)
-	:
induced	VBN
pulmonary	JJ
fibrosis	NN
.	.

A	DT
pharmacokinetic	JJ
study	NN
of	IN
HSA-Trx	NN
or	CC
Trx	NN
in	IN
BLM	NNP
mice	NNS
showed	VBD
that	IN
the	DT
plasma	NN
retention	NN
and	CC
lung	NN
distribution	NN
of	IN
Trxc	NN
was	VBD
markedly	RB
improved	VBN
by	IN
fusion	NN
with	IN
HSA	NN
.	.

A	DT
weekly	JJ
intravenous	JJ
administration	NN
of	IN
HSA-Trx	NN
,	,
but	CC
not	RB
Trx	NN
,	,
ameliorated	VBN
BLM-induced	JJ
fibrosis	NN
,	,
as	IN
evidenced	VBN
by	IN
a	DT
histopathological	JJ
analysis	NN
and	CC
pulmonary	JJ
hydroxyproline	NN
levels	NNS
.	.

HSA-Trx	NN
suppressed	VBD
active-transforming	JJ
growth	NN
factor	NN
(	(
TGF	NN
)	)
-	:
b	NN
levels	NNS
in	IN
the	DT
lung	NN
and	CC
inhibited	VBD
the	DT
increase	NN
of	IN
inflammatory	JJ
cells	NNS
in	IN
bronchoalveolar	JJ
lavage	NN
fluid	NN
,	,
pulmonary	JJ
inflammatory	JJ
cytokines	NNS
,	,
and	CC
oxidative	JJ
stress	NN
markers	NNS
.	.

An	DT
in	FW
vitro	FW
EPR	NN
experiment	NN
using	VBG
phosphate-buffered	JJ
saline-stimulated	JJ
neutrophils	NNS
confirmed	VBD
the	DT
O2	CD
(	(
-	:
)	)
scavenging	NN
ability	NN
of	IN
HSA-Trx	NN
.	.

Furthermore	RB
,	,
post-treatment	JJ
of	IN
HSA-Trx	NN
had	VBD
a	DT
suppressive	JJ
effect	NN
against	IN
BLM-induced	JJ
fibrosis	NN
.	.

These	DT
results	NNS
suggest	VBP
that	IN
HSA-Trx	NN
has	VBZ
potential	JJ
as	IN
a	DT
novel	JJ
therapeutic	JJ
agent	NN
for	IN
IPF	NN
,	,
because	IN
of	IN
its	PRP$
long-acting	JJ
antioxidative	JJ
and	CC
anti-inflammatory	JJ
modulation	NN
effects	NNS
.	.

